HS-10376

In the dose escalation phase, the safety and tolerability of HS-10376 administered orally in subjects with locally advanced or metastatic NSCLC will be evaluated by DLT, MTD, and other indicators. In the dose expansion phase, the efficacy of HS-10376 in subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 exon 20 insertion mutations will be determined by ORR based on investigator assessment. In the dose extension phase, the efficacy of HS-10376 in subjects with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations will be determined by ORR based on IRC assessment.